Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q2 2021 · 10-Q
Revenue$13.63M$13.63M+55.1% vs Q2 2020 Net Income$352.10K$352.10KN/M vs Q2 2020 EPS Diluted$0.02$0.02N/M vs Q2 2020 Gross Profit$8,044,675+56.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flowderived$189,904+48.8% Free Cash Flowderived$166,121+40.1% Margins · derivedGross margin59.0%+0.5 pt vs Q2 2020
Operating margin2.5%+14.5 pt vs Q2 2020
Net margin2.6%+14.9 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 4, 2021 · 35 d after period end